Tonix制药控股 TNXP 深 沪
交易中 07-02 11:04:18 美东时间
12.57
+0.130
+1.05%
华盛通- 最 高12.99
- 今 开12.63
- 成交量 13.06万股
- 最 低 12.50
- 昨 收 12.44
- 总市值 2.00亿
- 52周最高 69.97
- 市盈率 静 --
- 换手率 0.82%
- 52周最低 10.03
- 委 比 -50.00%
- 总股本 1594.08万
- 历史最高 13440000000.00
- 量 比 0.93
- 振 幅 3.94%
- 历史最低 10.03
- 每 手 1
- 风险率 10.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
Raymond James Initiates Coverage On Tonix Pharmaceuticals with Strong Buy Rating, Announces Price Target of $26
Raymond James analyst Tiago Fauth initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Strong Buy rating and announces Price Target of $26.
06-25 18:02
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026
Tonix Pharmaceuticals Holding Corp. announced that its management team, led by CEO Seth Lederman, will participate in 1x1 meetings at BTIG’s virtual Infectious Disease Day 2026 on June 16. Tonix is a biotech company focused on CNS and immunology treatments, with TONMYA as its flagship product for fibromyalgia. The company is also advancing clinical trials for TONMYA in major depressive disorder and acute stress disorder, while developing immunolo...
06-11 11:00
Tonix Shares Jump After Landing Second Commercial Payer Agreement For TONMYA
Tonix Pharmaceuticals Holding shares are trading higher Monday after securing second commercial payer agreement for fibromyalgia drug TONMYA.
06-08 20:41
Tonix Advances TNX-102 SL Into Phase 2 Depression Trial, Drawing Investor Focus
Tonix Pharmaceuticals ($TNXP) announced an update on their ongoing clinical stu...
06-03 00:31
Tonix Pharmaceuticals' ISPOR 2026 Data Show 93.2% Comorbidity Burden And $29,896 Annual Inpatient Costs Among Fibromyalgia Patients
Real-world analysis of three years of closed claims data from Symphony Health focused on the third year of the study (2023-2024), comprised of more than 261,000 U.S. adults with fibromyalgiaData underscore high
05-26 19:09
Tonix Pharmaceuticals posts TNX-4800 Lyme disease prevention presentation
Tonix Pharmaceuticals posts TNX-4800 Lyme disease prevention presentation Tonix Pharmaceuticals published a medical research presentation outlining TNX-4800, a long-acting, bactericidal human anti-OspA monoclonal antibody being developed to prevent Lyme disease in the U.S. Program concept centers on
05-18 21:52
Tonix publishes TNX-1500 xenotransplantation workshop presentation
Tonix publishes TNX-1500 xenotransplantation workshop presentation Tonix published a medical research presentation outlining its TNX-1500 anti-CD40L monoclonal antibody program for prevention of kidney transplant rejection, including applications in clinical xenotransplantation. The deck positions T
05-18 21:51
